<DOC>
	<DOC>NCT02722590</DOC>
	<brief_summary>The objective of this post-marketing surveillance study is to observe the safety profile of Fycompa film-coated tablets 2/4/6/8/10/12 milligrams (mg) in a normal clinical practice setting.</brief_summary>
	<brief_title>Post-Marketing Surveillance Study of Fycompa Film-coated Tablets in Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Participants with approved indication for Fycompa in Korea: the adjunctive therapy for treatment of partialonset seizures with or without secondarily generalized seizures in participants with epilepsy aged 12 years and older Participants who have written consent for use of personal and medical information for the study purpose Hypersensitivity to the active substance or to any of the excipients of this medicine Fycompa contains lactose; therefore, participants with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucosegalactose malabsorption should not take this medicine Other participants judged to be inadequate to participate in the study by doctor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-onset seizures</keyword>
	<keyword>secondarily generalized seizures</keyword>
</DOC>